Ropinirole
- PMID: 32119419
- Bookshelf ID: NBK554532
Ropinirole
Excerpt
Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. As a dopamine agonist, it acts on G-protein-coupled inhibitory neurons, inhibiting adenylyl cyclase and calcium channels while activating potassium channels. This mechanism maximizes the "on" time and minimizes the "off" time associated with disease progression, making ropinirole an attractive option for managing early and advanced-stage PD. Beyond its primary indications, ropinirole has also proved effective in addressing sleep disturbances and nocturnal symptoms linked to PD. This activity explores the applications of ropinirole and discusses its indications, contraindications, mechanism of action, adverse events, and essential considerations when using it as a therapy component.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
References
-
- Stocchi F, Radicati FG, Torti M. Drug safety evaluation of ropinirole prolonged release. Expert Opin Drug Saf. 2014 Mar;13(3):383-9. - PubMed
-
- Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000 Oct;39(4):243-54. - PubMed
-
- Muth CC. Restless Legs Syndrome. JAMA. 2017 Feb 21;317(7):780. - PubMed
-
- Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin. 2016 Nov;34(4):955-965. - PubMed
-
- Pahwa R, Lyons KE, Hauser RA. Ropinirole therapy for Parkinson's disease. Expert Rev Neurother. 2004 Jul;4(4):581-8. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials